SynAct () | Spotlight

The Swedish market will close at 13:00 on 2 April. The Norwegian and Danish markets will be closed on 2 April. On 3 and 6 April, the Swedish, Norwegian and Danish markets will be closed.

SynAct Pharma is a pharmaceutical group that conducts research and development in the treatment of inflammatory diseases. The company has developed a platform technology that is aimed at severe conditions in chronic inflammatory diseases, and foremost joint injuries. The subsidiary SynAct Pharma Aps was initially founded in 2012 and the parent company was established in 2016. The head office is located in Lund.

Quotes for SynAct Pharma AB

+/-
%




()

Board

CEO

Jeppe Øvlesen

Chairperson of the Board

Torbjørn Bjerke

Board

Kerstin Hasselgren
Marina Bozilenko
Terje Kalland
Thomas Jonassen
Uli Hacksell

Articles of association

News

2022-07-08 09:45:00 SynAct Pharma AB offentliggör prospekt för listbyte till Nasdaq Stockholm
2022-07-08 09:45:00 SynAct Pharma AB publishes prospectus for list change to Nasdaq Stockholm
2022-07-06 10:06:12 Spotlight: Market Notice 118/22 – SynAct Pharma AB will be delisted after close of the market on July 11, 2022
2022-06-29 18:00:00 SynAct Pharma får pre-IND-svar från amerikanska FDA
2022-06-29 18:00:00 SynAct Pharma recieves pre-IND response from the US FDA

Analysis

2019-11-29 Börsplus: Synact Pharma: Två skott mot mål - Börsplus

SynAct Pharma AB

Quotes for SynAct Pharma AB

Board

News

Analysis

Videos

Sedermeradagen Malmö 2018

SynAct Pharma - Life Science-dagen 2018

Styrelseordförande Torbjørn Bjerke på Aktiesparardagen i Lund

Styrelseledamot Charlotte Edenhus på Sedermeradagen i Stockholm

Annual reports, prospectus etc.